Cutting edge: TRAIL deficiency accelerates hematological malignancies

被引:135
作者
Zerafa, N
Westwood, JA
Cretney, E
Mitchell, S
Waring, P
Iezzi, M
Smyth, MJ
机构
[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Trescowthick Labs, Melbourne, Vic 8006, Australia
[2] Genentech Inc, Pathol & Diagnost, San Francisco, CA 94080 USA
[3] G DAnnunzio Univ Fdn, Aging Res Ctr, Chieti, Italy
关键词
D O I
10.4049/jimmunol.175.9.5586
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, > 25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted.
引用
收藏
页码:5586 / 5590
页数:5
相关论文
共 25 条
[11]  
Neville-Webbe HL, 2004, BREAST CANCER RES TR, V86, P269
[12]  
Pupa SM, 2005, CANCER RES, V65, P1071
[13]   T cells require TRAIL for optimal graft-versus-tumor activity [J].
Schmaltz, C ;
Alpdogan, O ;
Kappel, BJ ;
Muriglan, SJ ;
Rotolo, JA ;
Ongchin, J ;
Willis, LM ;
Greenberg, AS ;
Eng, JM ;
Crawford, JM ;
Murphy, GF ;
Yagita, H ;
Walczak, H ;
Peschon, JJ ;
van den Brink, MRM .
NATURE MEDICINE, 2002, 8 (12) :1433-1437
[14]  
Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO
[15]  
2-6
[16]   IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity [J].
Shankaran, V ;
Ikeda, H ;
Bruce, AT ;
White, JM ;
Swanson, PE ;
Old, LJ ;
Schreiber, RD .
NATURE, 2001, 410 (6832) :1107-1111
[17]   Differential tumor surveillance by natural killer (NK) and NKT cells [J].
Smyth, MJ ;
Thia, KYT ;
Street, SEA ;
Cretney, E ;
Trapani, JA ;
Taniguchi, M ;
Kawano, T ;
Pelikan, SB ;
Crowe, NY ;
Godfrey, DI .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :661-668
[18]   Nature's TRAIL - On a path to cancer immunotherapy [J].
Smyth, MJ ;
Takeda, K ;
Hayakawa, Y ;
Peschon, JJ ;
van den Brink, MRM ;
Yagita, H .
IMMUNITY, 2003, 18 (01) :1-6
[19]   Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma [J].
Smyth, MJ ;
Thia, KYT ;
Street, SEA ;
MacGregor, D ;
Godfrey, DI ;
Trapani, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) :755-760
[20]   Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis [J].
Smyth, MJ ;
Cretney, E ;
Takeda, K ;
Wiltrout, RH ;
Sedger, LM ;
Kayagaki, N ;
Yagita, H ;
Okumura, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) :661-670